The West Blog
March 10, 2021
Biosimilar development and approvals have been accelerated over the last several years. The rapid uptake in this category is due in large part to clarity on regulatory pathways that demonstrate interchangeability with the reference product and key patent expiry over the next decade. By 2025 injectable biosimilars are projected to comprise almost 50% of the accessible biologics market<sup>1</sup>. West recently conducted a survey of biosimilar companies to better understand their top needs for packaging and support services during drug development.